Inovio's VOCERYQ wins accelerated FDA approval for RRP, company reports Q3 2026 results
FDA cleared the first DNA medicine on October 30, 2026, as Inovio plans a 2027 launch and reports cash runway into late Q4 2027.
SEC filing (2)
5 stories
FDA cleared the first DNA medicine on October 30, 2026, as Inovio plans a 2027 launch and reports cash runway into late Q4 2027.
SEC filing (2)
The biotech set terms for a combined share and pre-funded warrant sale meant to fund the launch of its newly approved RRP therapy VOCERYQ, with delivery still pending.
FDA, SEC filing (3)
Inovio entered an underwriting agreement for shares and pre-funded warrants priced November 5, 2026, with closing anticipated on or about November 9.
SEC filing
Inovio said it expects to ship the RRP immunotherapy in about 60 days and must submit a confirmatory study protocol to the FDA by the end of 2026.
SEC filing, FDA press release (2)